The Editor's Roundtable: Bare-Metal Stents Versus Drug-Eluting Stents—Indications and Complications

      This CME activity is supported by an educational grant from Cordis Cardiology, Miami Lakes, Florida.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sigwart U.
        • Puel J.
        • Mirkovitch V.
        • Joffre F.
        • Kappenberger L.
        Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty.
        N Engl J Med. 1987; 316: 701-706
        • Kaul S.
        • Shah P.K.
        • Diamond G.A.
        As time goes by.
        J Am Coll Cardiol. 2007; 50: 128-137
        • Assali A.R.
        • Moustapha A.
        • Sdringola S.
        • Denktas A.E.
        • Willerson J.T.
        • Holmes D.R.
        • Smalling R.W.
        Acute coronary syndrome may occur with in-stent restenosis and is associated with adverse outcomes (the PRESTO trial).
        Am J Cardiol. 2006; 98: 729-733
        • Cutlip D.E.
        • Windecker S.
        • Mehran R.
        • Boam A.
        • Cohen D.J.
        • van Es G.-A.
        • Steg P.G.
        • Morel M.
        • Mauri L.
        • Vranckx P.
        • et al.
        • Academic Research Consortium
        Clinical end points in coronary stent trials: a case for standardized definitions.
        Circulation. 2007; 115: 2344-2351
        • Steinhubl S.R.
        • Berger P.B.
        • Mann J.T.
        • CREDO Investigators
        Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention.
        JAMA. 2002; 288: 2411-2420
        • United States Food and Drug Administration
        FDA statement on coronary drug-eluting stents (September 14, 2006).
        (Accessed November 10, 2007)